Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study (Q47949741)

7 February 2018

title

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study (English)

1 reference

7 February 2018

1 reference

15

1 reference

7 February 2018

Youssef Daali

8

object named as

Youssef Daali

1 reference

7 February 2018

Alwin D R Huitema

7

object named as

Alwin D R Huitema

1 reference

7 February 2018

Jan H M Schellens

13

object named as

Jan H M Schellens

1 reference

7 February 2018

author name string

Jacqueline S L Kloth

1

1 reference

7 February 2018

Heinz-Josef Klümpen

2

1 reference

7 February 2018

Huixin Yu

3

1 reference

7 February 2018

Karel Eechoute

4

1 reference

7 February 2018

Caroline F Samer

5

1 reference

7 February 2018

Boen L R Kam

6

1 reference

7 February 2018

Aeilko H Zwinderman

9

1 reference

7 February 2018

Bavanthi Balakrishnar

10

1 reference

7 February 2018

Roelof J Bennink

11

1 reference

7 February 2018

Mark Wong

12

1 reference

7 February 2018

Ron H J Mathijssen

14

1 reference

7 February 2018

publication date

1 March 2014

1 reference

7 February 2018

Clinical Pharmacokinetics

published in

1 reference

7 February 2018

volume

53

1 reference

7 February 2018

issue

3

1 reference

7 February 2018

page(s)

261-269

1 reference

7 February 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Determining the best dose for the individual patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0111-4

Without therapeutic drug monitoring, there is no personalized cancer care

21 January 2018

1 reference

12 December 2020

Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo

1 reference

12 December 2020

Genomics and drug response

1 reference

12 December 2020

Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

1 reference

12 December 2020

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity

1 reference

12 December 2020

Daily rhythmic variation in hepatic drug metabolism in the rat and mouse

1 reference

12 December 2020

10.1007/S40262-013-0111-4

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018